Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Strattera and Exelon for Attention in Parkinson's Disease
NCT01340885Phase 4Completed
- Sponsor
- Oregon Health & Science University
- Start
- Jan 2011
- Primary completion
- Jan 2013
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of atomoxetine, rivastigmine in Parkinson's disease (PD), sponsored by Oregon Health & Science University. Started Jan 2011; status: completed.
02
Drugs
atomoxetinerivastigmine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01340885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01340885.